AllCells, LLC: New Mobilized Peripheral Blood Products

Published: Apr 01, 2013

April 1, 2013 -- AllCells is excited to announce the launch of our new mobilized peripheral blood products including two types of CD34+ cells mobilizing agents: Granulocyte-Colony Stimulating Factor (G-CSF, Neupogen®) and Plerixafor (Mozobil®) through IRB approved protocols. It has been shown that mobilizing agents can significantly increase the number of bone marrow-derived circulating CD34+ cells in peripheral blood. Clinically, mobilizing agents have been used for transplantation with bone marrow hematopoietic stem cells in curative therapies of hematologic diseases and inborn errors of metabolism.

Granulocyte-Colony Stimulating Factor (G-CSF, Neupogen®) can stimulate bone marrow to produce a large number of hematopoietic stem/progenitor cells. G-CSF can mobilize these stem/progenitor cells from bone marrow into the peripheral blood stream.

The effects of G-CSF have changed the practice of bone marrow transplantation. Consequently, mobilized peripheral blood cells have become major sources for clinical hematopoietic stem cell transplantation.

In addition AllCells now offers Plerixafor (Mozobil®) mobilization of stem cells from healthy donors. Mozobil, a selective CXCR4 antagonist, has been particularly beneficial as an adjuvant stem cell mobilization agent on top of the G-CSF regimen. The Mozobil regimen requires only 1 injection as opposed to the G-CSF 3-5 day protocol. AllCells is currently the only source of Plerixafor-mobilized cells in the world. For more information on this exciting new mobilization agent visit our Mobilized Peripheral Blood section.

Our mobilized peripheral blood products have many applications including:

• Study post-stimulation effects of Neupogen® (G-CSF) or Mozobil® (Plerixafor) on general profiles and individual MNC phenotypes

• Enrich CD34+ human stem cells for further culture and characterization studies

To learn more, visit our mobilized peripheral blood products page.

About AllCells, LLC is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells and bioservices that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. Now, we also offer a line of Bioservices featuring immunoassays, stem cell assays, flow cytometry services, tissue culture services, protein analysis, and protein analysis. AllCells is fully certified in accordance with local, state and federal requirements.

Back to news